Cadrenal Therapeutics reports Q1 2023 cash of $4M, Fast Track for tecarfarin

Cadrenal Therapeutics, Inc.

FDA granted Fast Track designation for tecarfarin in ESRD/AFib patients in Jan 2023.
Completed IPO raising $7.0M gross proceeds; cash at March 31, 2023 was $4.0M.
Q1 2023 operating expenses (ex-non-cash) were $913,653; cash expected to fund through Q2 2024.
Plans Phase 3 ACTOR-AF trial (492 patients) as pivotal step before NDA submission.
Market opportunity for tecarfarin estimated up to $1B annually if FDA approved.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Cadrenal Therapeutics, Inc. reported preliminary financial results for the fiscal quarter ended March 31, 2023.

Period: the fiscal quarter ended March 31, 2023
Result: preliminary results

Exact text from the filing

On May 10, 2023, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Cadrenal Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-037928

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.